Physician profile
Temitope A Adeleke
NPI 1104439553
$862.91
in general payments reported to CMS, 2019-2025
8 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.07 · 2023: $27.88 · 2024: $159 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $317.30 | 2022-2025 | Sublocade |
| Abbvie INC. | $201.76 | 2025 | |
| Gilead Sciences, INC. | $107.95 | 2024-2025 | Epclusa |
| Braeburn INC. | $88.51 | 2024-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $49.83 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $43.13 | 2022-2024 | Vivitrol |
| Orexo US, INC. | $37.18 | 2024-2025 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.25 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temitope Adeleke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.